Gastroduodenal toxicity of low-dose acetylsalicylic acid: a comparison with non-steroidal anti-inflammatory drugs

References

• Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 2006;1:74-7
   Google Scholar
• National Health Service Information Centre. Prescription cost analysis for England 2007. 2008. Available at: http://www.ic.nhs.uk/webfiles/publications/PCA%20publication/PCA%202007%20complete%20V2.pdf [Last Accessed 22 April 2009]
   Google Scholar
• Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349-60
   PubMedGoogle Scholar
• Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl.):234S-64S
   PubMedGoogle Scholar
• Chan AT, Manson JE, Feskanich D, et al. Long-term aspirin use and mortality in women. Arch Intern Med 2007;167:562-72
   PubMed Web of Science ®Google Scholar
• Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994;308:81-106
   PubMedGoogle Scholar
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
   Google Scholar
• Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008;121:43-9
   PubMed Web of Science ®Google Scholar
• Taha AS, Angerson WJ, Knill-Jones RP, et al. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs – a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005;22:285-9
   PubMed Web of Science ®Google Scholar
• Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002;50:460-4
   PubMed Web of Science ®Google Scholar
• Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-91
   PubMed Web of Science ®Google Scholar
• Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007;23:134-41
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99
   PubMed Web of Science ®Google Scholar
• Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem. J Gastroenterol 1997;32:127-33
   PubMed Web of Science ®Google Scholar
• Dhikav V, Singh S, Pande S, et al. Non-steroidal drug-induced gastrointestinal toxicity: mechanisms and management. J Indian Acad Clin Med 2003;4:315-22
   Google Scholar
• Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297:2018-24
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81
   PubMed Web of Science ®Google Scholar
• Guslandi M. Gastric toxicity of antiplatelet therapy with low-dose aspirin. Drugs 1997;53:1-5
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83
   PubMed Web of Science ®Google Scholar
• Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617
   PubMed Web of Science ®Google Scholar
• Chvasta TE, Cooke AR. The effect of several ulcerogenic drugs on the canine gastric mucosal barrier. J Lab Clin Med 1972;79:302-15
   PubMed Web of Science ®Google Scholar
• Hingson DJ, Ito S. Effect of aspirin and related compounds on the fine structure of mouse gastric mucosa. Gastroenterology 1971;61:156-77
   PubMed Web of Science ®Google Scholar
• Hogben CA, Schanker LS, Tocco DJ, et al. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957;120:540-5
   PubMed Web of Science ®Google Scholar
• Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7
   PubMed Web of Science ®Google Scholar
• Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002;16:1945-53
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218-24
   PubMed Web of Science ®Google Scholar
• Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, McQuay HJ. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther 2008;10:R7
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9
   PubMed Web of Science ®Google Scholar
• Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25
   PubMed Web of Science ®Google Scholar
• A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N Engl J Med 1991;325:1261-6
   Google Scholar
• Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13
   PubMed Web of Science ®Google Scholar
• Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008;103:2465-73
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005;95:1218-22
   PubMed Web of Science ®Google Scholar
• McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-38
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004;159:23-31
   PubMed Web of Science ®Google Scholar
• Leivonen M, Sipponen P, Kivilaakso E. Gastric changes in coronary-operated patients with low-dose aspirin. Scand J Gastroenterol 1992;27:912-16
   PubMed Web of Science ®Google Scholar
• Niv Y, Battler A, Abuksis G, et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 2005;50:78-80
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Thiefin G, Montalescot G, Woimant F, et al. Prevalence and clinical impact of upper gastrointestinal symptoms in patients treated with low dose aspirin [abstract W1925]. Gastroenterology 2008;134(Suppl. 1):A-735
   Google Scholar
• Ford AC, Moayyedi P. Current guidelines for dyspepsia management. Dig Dis 2008;26:225-30
   PubMed Web of Science ®Google Scholar
• Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004;110:2361-7
   PubMed Web of Science ®Google Scholar
• Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med 2005;257:399-414
   PubMed Web of Science ®Google Scholar
• Marco J, Amariles P, Bosca B, et al. Risk factors associated with NSAID induced upper gastrointestinal bleeding resulting in hospital admissions: a cross sectional, retrospective, case series analysis in Valencia, Spain. Curr Ther Res 2007;68:107-19
   PubMed Web of Science ®Google Scholar
• Taha AS, Angerson WJ, Prasad R, et al. Upper gastrointestinal bleeding and the changing use of COX-2 non-steroidal anti-inflammatory drugs and low-dose aspirin. Aliment Pharmacol Ther 2007;26:1171-8
   PubMed Web of Science ®Google Scholar
• Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006;4:22
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001;1:1
   PubMedGoogle Scholar
• Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8
   PubMed Web of Science ®Google Scholar
• Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351:233-41
   Google Scholar
• Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002;35:413-21
   PubMed Web of Science ®Google Scholar
• Thomopoulos KC, Mimidis KP, Theocharis GJ, et al. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J Gastroenterol 2005;11:1365-8
   PubMed Web of Science ®Google Scholar
• Cohen MM, MacDonald WC. Mechanism of aspirin injury to human gastroduodenal mucosa. Prostaglandins Leukot Med 1982;9:241-55
   PubMedGoogle Scholar
• Darling RL, Romero JJ, Dial EJ, et al. The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin metabolism in cyclooxygenase knockout mice. Gastroenterology 2004;127:94-104
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437
   PubMed Web of Science ®Google Scholar
• Hogan DL, Ainsworth MA, Isenberg JI. Review article: gastroduodenal bicarbonate secretion. Aliment Pharmacol Ther 1994;8:475-88
   PubMed Web of Science ®Google Scholar
• Johansson C, Aly A, Befrits R, et al. Protection of the gastroduodenal mucosa by prostaglandins. Scand J Gastroenterol Suppl 1985;110:41-8
   PubMedGoogle Scholar
• Cole AT, Hudson N, Liew LC, et al. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?. Aliment Pharmacol Ther 1999;13:187-93
   PubMed Web of Science ®Google Scholar
• Arai I, Hirose H, Muramatsu M, et al. Possible involvement of non-steroidal anti-inflammatory drugs in vagal-mediated gastric acid secretion in rats. Jpn J Pharmacol 1985;37:91-9
   PubMedGoogle Scholar
• Jaramillo E, Mardh S, Green K, et al. The effect of arachidonic acid and its metabolites on acid production in isolated human parietal cells. Scand J Gastroenterol 1989;24:1231-7
   PubMed Web of Science ®Google Scholar
• Wang GZ, Huang GP, Yin GL, et al. Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. Cell Physiol Biochem 2007;20:205-12
   PubMed Web of Science ®Google Scholar
• Myers CP, Hogan D, Yao B, et al. Inhibition of rabbit duodenal bicarbonate secretion by ulcerogenic agents: histamine-dependent and -independent effects. Gastroenterology 1998;114:527-35
   PubMed Web of Science ®Google Scholar
• Bennett A, Stamford IF, Unger WG. Prostaglandin E2 and gastric acid secretion in man. J Physiol 1973;229:349-60
   PubMed Web of Science ®Google Scholar
• Venerito M, Treiber G, Wex T, et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:1225-33
   PubMed Web of Science ®Google Scholar
• Padol IT, Mana F, Wang C-C, et al. Strain specific genetic background determines the differential in vivo effect of prostaglandins and NSAIDs on acid secretion in the mouse [abstract S1735]. Gastroenterology 2005;128(Suppl. 2):A-245
   Google Scholar
• Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86:449-58
   PubMed Web of Science ®Google Scholar
• White WB. Cardiovascular aspects of prostaglandin inhibition: focus on the COX-2 specific inhibitors. Cardiovasc Rev Rep 2003;24:214-19
   Google Scholar
• Cryer B, Kliewer D, Sie H, et al. Effects of cutaneous aspirin on the human stomach and duodenum. Proc Assoc Am Physicians 1999;111:448-56
   PubMedGoogle Scholar
• Skeljo MV, Giraud AS, Yeomans ND. Gastric mucosal damage induced by nonsalicylate nonsteroidal antiinflammatory drugs in rats is mediated systemically. Dig Dis Sci 1993;38:2038-42
   PubMed Web of Science ®Google Scholar
• van Oijen MG, Dieleman JP, Laheij RJ, et al. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin Gastroenterol Hepatol 2008;6:309-13
   PubMed Web of Science ®Google Scholar
• Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther 2008;46:180-6
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8
   PubMed Web of Science ®Google Scholar
• Hawkey CJ. NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. Clin Exp Rheumatol 2001;19(Suppl. 25):S23-30
   PubMedGoogle Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55
   PubMed Web of Science ®Google Scholar
• Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin 2007;23:2985-95
   PubMed Web of Science ®Google Scholar
• Sopena F, Lanas A. How to advise aspirin use in patients who need NSAIDs. Curr Pharm Des 2007;13:2248-60
   PubMed Web of Science ®Google Scholar
• Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005;45:1295-301
   PubMed Web of Science ®Google Scholar
• Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17
   PubMed Web of Science ®Google Scholar
• Geall MG, Phillips SF, Summerskill WH. Profile of gastric potential difference in man. Effects of aspirin, alcohol, bile, and endogenous acid. Gastroenterology 1970;58:437-43
   PubMed Web of Science ®Google Scholar
• Baskin WN, Ivey KJ, Krause WJ, et al. Aspirin-induced ultrastructural changes in human gastric mucosa: correlation with potential difference. Ann Intern Med 1976;85:299-303
   PubMed Web of Science ®Google Scholar
• O’Laughlin JC, Hoftiezer JW, Ivey KJ. Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours, and 2 weeks after administration. Scand J Gastroenterol Suppl 1981;67:211-14
   PubMedGoogle Scholar
• Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996;55:211-13
   PubMed Web of Science ®Google Scholar
• Ligumsky M, Golanska EM, Hansen DG, et al. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat. Gastroenterology 1983;84:756-61
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Mahida YR, Cole AT, et al. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis. Br J Clin Pharmacol 1991;32:77-83
   PubMed Web of Science ®Google Scholar
• Venerito M, Treiber G, Wex T, et al. Short-term/low-dose aspirin-induced duodenal erosions are not dependent on Helicobacter pylori infection, cyclooxygenase expression and prostaglandin E2 levels. Scand J Gastroenterol 2008;43:801-9
   PubMed Web of Science ®Google Scholar
• Dammann HG, Burkhardt F, Wolf N. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions. Aliment Pharmacol Ther 1999;13:1109-14
   PubMed Web of Science ®Google Scholar
• Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-16
   PubMed Web of Science ®Google Scholar
• Chowdhury A, Ganguly G, Chowdhury D, et al. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study. Indian J Gastroenterol 2001;20:227-9
   PubMedGoogle Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001;52:563-71
   PubMed Web of Science ®Google Scholar
• Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 1999;107(6A):27S-35S; discussion S-6S
   PubMedGoogle Scholar
• Bjarnason I, Scarpignato C, Takeuchi K, et al. Determinants of the short-term gastric damage caused by NSAIDs in man. Aliment Pharmacol Ther 2007;26:95-106
   PubMed Web of Science ®Google Scholar
• Bjarnason I, Hayllar J. Early pathogenic events in NSAID-induced gastrointestinal damage. Ital J Gastroenterol 1996;28(Suppl. 4):19-22
   PubMedGoogle Scholar
• Lichtenberger LM, Richards JE, Hills BA. Effect of 16,16-dimethyl prostaglandin E2 on the surface hydrophobicity of aspirin-treated canine gastric mucosa. Gastroenterology 1985;88:308-14
   PubMed Web of Science ®Google Scholar
• Oh KW, Qian T, Brenner DA, et al. Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicol Sci 2003;73:44-52
   PubMed Web of Science ®Google Scholar
• Konturek PC, Kania J, Hahn EG, et al. Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase. J Physiol Pharmacol 2006;57(Suppl. 5):125-36
   PubMedGoogle Scholar
• Kamada G, Kato M, Asaka M, et al. Evaluation of gastric mucosal blood flow using contrast enhanced ultrasonography during low dose aspirin therapy and during NSAID and low dose aspirin combined therapy [abstract M1114]. Gastroenterology 2008;134(Suppl. 1):A-341
   Google Scholar
• Odashima M, Otaka M, Ohba R, et al. Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phosphodiesterase in rats. Dig Dis Sci 2007;52:1355-9
   PubMed Web of Science ®Google Scholar
• Power JJ, Dennis MS, Redlak MJ, et al. Aspirin-induced mucosal cell death in human gastric cells: evidence supporting an apoptotic mechanism. Dig Dis Sci 2004;49:1518-25
   PubMed Web of Science ®Google Scholar
• Redlak MJ, Power JJ, Miller TA. Aspirin-induced apoptosis in human gastric cancer epithelial cells: relationship with protein kinase C signaling. Dig Dis Sci 2007;52:810-16
   PubMed Web of Science ®Google Scholar
• Alderman BM, Cook GA, Familari M, et al. Resistance to apoptosis is a mechanism of adaptation of rat stomach to aspirin. Am J Physiol Gastrointest Liver Physiol 2000;278:G839-46
   PubMed Web of Science ®Google Scholar
• Leung AM, Redlak MJ, Miller TA. Aspirin induced mucosal cell death in human gastric cells: evidence supporting a caspase independent mechanism [abstract W1943]. Gastroenterology 2008;134(Suppl. 1):A-739
   Google Scholar
• Zhu GH, Wong BC, Slosberg ED, et al. Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology 2000;118:507-14
   PubMed Web of Science ®Google Scholar
• Laine L. Review article: gastrointestinal bleeding with low-dose aspirin – what's the risk?. Aliment Pharmacol Ther 2006;24:897-908
   PubMed Web of Science ®Google Scholar
• Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007;23:163-73
   PubMed Web of Science ®Google Scholar
• Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:1038-9
   PubMed Web of Science ®Google Scholar
• Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study [Abstract]. Circulation 2008;118(18):S815, Abs 3998
   Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Can Med Assoc J 2009;180(7): DOI:10.1503/cmaj.082001
   Web of Science ®Google Scholar
• Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [Abstract]. Circulation 2008;118(18):S_815, Abs 3999
   Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360(4):363-75
   PubMed Web of Science ®Google Scholar
• Zairis M, Patsourakos N, Makrygiannis S, et al. The impact of oral proton pump inhibitors on the effectiveness of combined aspirin and clopidogrel drug therapy during the first year after elective coronary stenting. European Heart Journal 2008;29(Suppl):abstr.134
   Google Scholar
• Ramirez JF, Selzer F, Chakaprani R, et al. Proton pump inhibitor and clopidogrel combination is not associated with adverse clinical outcomes after PCI: the NHLBI dynamic registry. J Am Coll Cardiol 2009;53(10 suppl 1):Abstr. 2903-7
   Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
   PubMed Web of Science ®Google Scholar
• O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet Published online Sept 1, 2009 DOI:10.1016/S0140-736(09)61525-7
   Google Scholar
• Nishino M, Sugimoto M, Kodaira C, et al. Study of relationship between intragastric pH and gastric mucosal lesions induced by low dose aspirin in healthy volunteers [abstract W1920]. Gastroenterology 2008;134(Suppl. 1):A-734
   Google Scholar
• Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-909
   PubMed Web of Science ®Google Scholar
• Irani S, Krevsky B, Desipio J, et al. Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole. Aliment Pharmacol Ther 2008;27:498-503
   PubMed Web of Science ®Google Scholar
• Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003;18:443-9
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005;352:238-44
   PubMed Web of Science ®Google Scholar
• Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006;4:860-5
   PubMed Web of Science ®Google Scholar
• Kitchingman GK, Prichard PJ, Daneshmend TK, et al. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine. Br J Clin Pharmacol 1989;28:581-5
   PubMed Web of Science ®Google Scholar
• Cole AT, Brundell S, Hudson N, et al. Ranitidine: differential effects on gastric bleeding and mucosal damage induced by aspirin. Aliment Pharmacol Ther 1992;6:707-15
   PubMed Web of Science ®Google Scholar
• Donnelly MT, Goddard AF, Filipowicz B, et al. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000;14:529-34
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Huang B, Amer F, et al. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004;26:1637-43
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9
   PubMed Web of Science ®Google Scholar